Patent US4186183A successfully refreshed from Google Patents.
US4186183A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liposome carriers in chemotherapy of leishmaniasis
Assignee: United States Department of the Army
•
Filing: 1978-03-29
•
Granted: 1980-01-29
•
Expires: 1998-03-29
Abstract
Abstract An improved method is provided for the chemotherapy of leishmanial infections. The anti-leishmanial agent is encapsulated within liposomes and the liposome-encapsulated drug is injected into the body. Subject use of a liposome carrier has produced marked enhancement of the effectiveness and duration of anti-leishmanial action of meglumine antimoniate, and of sodium stibogluconate, drugs which are recommended widely for therapy of leishmaniasis.
Inventors
- 👤 Edgar A. Steck
- 👤 Carl R. Alving
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:58
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K31/00; A61K31/13; A61K31/185; A61K31/19; A61K9/1277; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
81 words
The product prepared by a process for encapsulating an antimonial drug with liposomes comprising the steps of: a. drying a lipid mixture to form a dry film; b. wetting the lipid film with an aqueous solution of the antimonial drug; c. mixing the aqueous solution of antimonial drug and lipid film to form a suspension of antimonial drug encapsulated by liposomes; d. separating the liposome-encapsulated drug; and e. washing the liposome-encapsulated antimonial drug to remove substantially all nonencapsulated antimonial drug therefrom.
Claim 2
Dependent Claim
81 words
The product prepared by a process for encapsulating an antimonial drug with liposomes comprising the steps of: a. drying a lipid mixture to form a dry film; b. wetting the lipid film with an aqueous solution of the antimonial drug; c. mixing the aqueous solution of antimonial drug and lipid film to form a suspension of antimonial drug encapsulated by liposomes; d. separating the liposome-encapsulated drug; and e. washing the liposome-encapsulated antimonial drug to remove substantially all nonencapsulated antimonial drug therefrom.
Claim 3
Dependent Claim
25 words
A method for the chemotherapy treatment of leishmaniasis by administering to an infected animal a leishmanicidally effective amount of liposome-encapsulated antimonial drug of claim 1.
Claim 4
Dependent Claim
18 words
The method of claim 2 wherein the lipid mixture in step (a) consists of a phospholipid and cholesterol.
Claim 5
Dependent Claim
22 words
The method of claim 2 wherein the lipid mixture in step (a) consists of a phospholipid, cholesterol, and a charged amphipathic compound.
Claim 6
Dependent Claim
27 words
The method of claim 4 wherein the phospholipid is selected from the group consisting of a phosphatidyl choline derivative, a glycerophosphatide, a lysophosphatide, sphingomyclin, and mixtures thereof.
Claim 7
Dependent Claim
27 words
The method of claim 4 wherein the amphipathic compound is selected from the group consisting of a di (alkyl) phosphate, a phosphatidic acid and a phosphatidyl serine.
Claim 8
Dependent Claim
23 words
The method of claim 4 wherein the amphipathic compound is selected from the group consisting of dicetyl phosphate, dilauryl phosphate, stearylamine and hexadecylamine.
Claim 9
Dependent Claim
12 words
The method of claim 2 wherein the antimonial drug is meglumine antimoniate.
Claim 10
Dependent Claim
12 words
The method of claim 2 wherein the antimonial drug is sodium stibogluconate.
Claim 11
Dependent Claim
12 words
The method of claim 3 wherein the antimonial drug is meglumine antimoniate.
Claim 12
Dependent Claim
12 words
The method of claim 3 wherein the antimonial drug is sodium stibogluconate.
Claim 13
Dependent Claim
12 words
The method of claim 4 wherein the antimonial drug is meglumine antimoniate.
Claim 14
Dependent Claim
12 words
The method of claim 4 wherein the antimonial drug is sodium stibogluconate.
Claim 15
Dependent Claim
12 words
The method of claim 5 wherein the antimonial drug is meglumine antimoniate.
Claim 16
Dependent Claim
12 words
The method of claim 5 wherein the antimonial drug is sodium stibogluconate.
Claim 17
Dependent Claim
20 words
The method of claim 7 wherein the charged amphipathic lipid is selected from the group consisting of stearylamine and hexadecylamine.
Claim 18
Dependent Claim
26 words
The method of claim 7 wherein the charged amphipathic compound is selected from the group consisting of dicetyl phosphate, dilauryl phosphate, phosphatidyl serine, and phosphatidic acid.
Claim 19
Dependent Claim
18 words
A composition for the chemotherapy treatment of leishmaniasis comprising a leishmanicidally effective amount of a liposome-encapsulated antimonial drug.
Claim 20
Dependent Claim
18 words
A composition for the chemotherapy treatment of leishmaniasis comprising a leishmanicidally effective amount of a liposome-encapsulated antimonial drug.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-01-28 | 1983-07-30 | 1984-01-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-01-28 | 1987-07-30 | 1988-01-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-01-28 | 1991-07-30 | 1992-01-29 | $7700.00 | Window Closed / Lapsed |